Bioproduction: a strategic sector
The bioproduction of tomorrow could be the cure for the incurable diseases of today. From different types of cancer to degenerative illnesses, from rare diseases to certain chronic disorders, biomedicines such as vaccines and antibiotics could provide patients with more solutions. With the emergence of new technologies, it is now possible to contemplate totally disruptive approaches in biotech that will produce innovative therapies that are not only affordable but also closer to patient needs and the specificities of their illness. Although biomedicines today only make up 30% of the total drug market, by 2025 they will represent 50% of the most commonly-prescribed drugs.
What is the main challenge today? Making these drugs accessible to patients. This involves, on the one hand, prioritising their development and industrialising production in France, while guaranteeing the right quantity, the required quality, the speed of production and affordable costs. On the other, it means helping to build France’s health independence on the world stage so that we can guarantee that the most innovative treatments are available to patients. Today, France is 95% dependent on imports for biotherapies. But this figure is not set in stone: with a bioproduction sector that currently employs 8,500 people, the French industrial network aims to assert its independence in the years ahead.
Health bioproduction: a sector with a future
The French sector has mobilised throughout the country as part of the Investing for the Future programme via a special agreement entered into by the Strategic Committee for the Health Industry and Technology Sector. The Committee has set up around 20 technological breakthrough projects, including a training platform for preparing the talents of tomorrow: immerscio.bio. This campus was born out of a desire to develop and promote new skills with a training programme that is different from anything that existed before in the field of bioproduction. Led by a top-tier industrial consortium (bioMérieux, Novasep, Sanofi and Servier), Immerscio.bio brings together the entire national biotech ecosystem, including schools and training bodies.
Why work in the bioproduction professions?
The bioproduction sector is particularly buoyant for students, young working people or employees following a vocational retraining: 30,000 to 40,000 jobs will need to be filled in the next ten years in Europe.
Could this be an opportunity to make the move towards professions with a purpose – jobs whose importance has been highlighted by the health crisis linked to the COVID-19 pandemic? Working in biotechnologies means striving to develop new treatments and future therapies that will benefit everyone’s health against the background of an aging population and the emergence of new diseases. This involves fighting to treat diseases that have been incurable until now: bioproduction can push back the boundaries of what is possible in the field by devising state-of-the-art therapeutic solutions.
Bioproduction is also a very stimulating professional environment that is geared towards innovation, where it is possible to acquire cutting-edge qualifications in the occupations of the future. These jobs, which are often little-known, require meticulousness, rigour and a taste for teamwork.
Immerscio.bio offers bespoke training programmes embracing the entire chain of bioproduction occupations by means of immersive, innovative courses where digital and technological tools play a major role in the learning methods. Choosing Immerscio.bio means boosting your employability on the job market and giving purpose to your career so you can take part in the innovative therapies of tomorrow.